Tillman D M, Adams F G, Gillen G, Morton J J, Robertson J I
Am J Cardiol. 1987 Apr 24;59(10):133D-142D. doi: 10.1016/0002-9149(87)90068-3.
The converting enzyme inhibitor, ramipril, 20 mg once daily, was given to 3 hypertensive patients with unilateral renovascular disease. At 1 month, 24 hours after the last dose of ramipril, blood pressure, plasma angiotensin II and converting enzyme activity remained low, and active renin and angiotensin I high. There was no tendency for converting enzyme inhibition to be overcome during 1 month of ramipril therapy. Ramipril caused slight increases in serum potassium and urea, no change in serum creatinine and no consistent changes in the renal vein renin ratio. Ramipril caused little change in renal plasma flow on the stenotic side, but filtration fraction was reduced in 2 patients. There was no serious deterioration in total or individual glomerular filtration rate during ramipril therapy. The drug was well tolerated and there were no serious side effects. Ramipril, given once daily, is likely to be effective in controlling hypertension with renal artery stenosis.
给3例单侧肾血管疾病的高血压患者服用转换酶抑制剂雷米普利，每日1次，每次20毫克。1个月时，在最后一剂雷米普利给药24小时后，血压、血浆血管紧张素II和转换酶活性仍较低，而活性肾素和血管紧张素I较高。在雷米普利治疗的1个月期间，没有出现转换酶抑制被克服的趋势。雷米普利使血清钾和尿素略有升高，血清肌酐无变化，肾静脉肾素比值无一致变化。雷米普利使狭窄侧肾血浆流量变化不大，但2例患者的滤过分数降低。在雷米普利治疗期间，总肾小球滤过率或单个肾小球滤过率均未出现严重恶化。该药物耐受性良好，无严重副作用。每日服用1次雷米普利可能对控制肾动脉狭窄引起的高血压有效。
